Jeffrey Weiss, MD
Rheumatology · New York, NYNPI 1316946247
Payments from drug & device makers
Across 73 payments — averaging $82.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- Mallinckrodt Enterprises LLC$316
- Bristol Myers Squibb$270
- Mallinckrodt Hospital Products Inc.$261
- Amgen$226
- Pfizer$116
- plus $271 from 6 others
What the payments were for
- Consulting fees$4,61077%
- Food & beverage$1,40923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $4,560 |
| Mallinckrodt Enterprises LLC | 16 | $316 |
| Bristol Myers Squibb | 12 | $270 |
| Mallinckrodt Hospital Products Inc. | 12 | $261 |
| Amgen(2 entities) | 12 | $226 |
| Pfizer | 6 | $116 |
| Cardinal Health 110 LLC | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 2 | $59 |
| Sanofi-aventis U.S. LLC | 1 | $44 |
| GSK | 2 | $29 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| UCB, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$4,510
- SIMPONI ARIA$4,510
- Tremfya$750
- Otezla$139
How this compares
$6,019 in reported general payments places this provider in the 60th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 48 | $274,031 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $6,848 |
| Diclofenac Sodium | 54 | $1,079 |
| Gabapentin | 36 | $694 |
| Ibandronate Sodium | 12 | $559 |
| Duloxetine Hcl | 15 | $483 |
| Oxycodone Hcl | 35 | $473 |
| MethotrexateMethotrexate Sodium | 15 | $259 |
| Atorvastatin Calcium | 13 | $105 |
| Meloxicam | 12 | $88 |
| Cyclobenzaprine Hcl | 16 | $64 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in New York
- Amit SaxenaNew York$6.7M
- Robert SpieraNew York$4.3M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Laura Geraldino PardillaNew York$1.7M
- Joan BathonNew York$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.